Instruction for use: Ascaff

Active substance Acetylsalicylic acid + Caffeine

ATX Code N02BA71 Acetylsalicylic acid in combination with psycholeptics

Pharmacological groups

NSAIDs - Salicylic acid derivatives in combinations

Nosological classification (ICD-10)

K13.7 Other and unspecified lesions of oral mucosa

Aspirin burn of the oral mucosa, Gum pain when wearing dentures, Inflammation of the mouth, Inflammation of the oral mucosa, Inflammation of the oral mucosa after radiation therapy, Inflammation of the oral mucosa after chemotherapy, Inflammation of the oral mucosa, Inflammation of the mucous membranes of the mouth, Inflammatory diseases of the oral cavity, Inflammatory process of pharynx, Disease of the oral mucosa, Injuries to the oral cavity and larynx, Injuries of the oral mucosa, Trophic diseases of the oral mucosa, Erosive-ulcerative periodontal disease, Erosive-ulcerative lesion of the oral mucosa, Erotic mucous membrane of the oral cavity, Erotic-ulcerative periodontal lesions, Erotic-ulcerative lesions of the oral mucosa, Radio-epileleitis, Irritation from dental prostheses, Irritation of the oral mucosa with dentures and braces, Oral cavity, When wearing dentures

M25.5 Pain in the joint

Arthralgia, Pain syndrome in musculo-articular diseases, Pain syndrome in osteoarthritis, Pain syndrome in osteoarthritis, Pain syndrome in acute inflammatory diseases of the musculoskeletal system, Pain syndrome in chronic inflammatory diseases of the musculoskeletal system, Pain in the joints, Soreness of the joints, Soreness of joints in severe physical exertion, Painful inflammatory joint damage, Painful conditions of the musculoskeletal system, Painful joint conditions, Painful traumatic affection of joints, Pain in the musculoskeletal system, Pain in Shoulder Joints, Pain in the joints, Joint pain, Joint pain with injuries, Musculoskeletal pain, Pain with osteoarthritis, Pain in the pathology of the joints, Pain in rheumatoid arthritis, Pain in chronic degenerative bone diseases, Pain in chronic degenerative joint diseases, Bone-joint pain, Joint pain, Arthritic pain of rheumatic origin, Articular pain syndrome, Joint pain, Rheumatic pain, Rheumatic pains

M79.1 Myalgia

Myofascial pain syndromes ,Pain syndrome in musculo-articular diseases, Pain syndrome in chronic inflammatory diseases of the musculoskeletal system, Pain in the muscles, Tenderness of muscles, Muscular soreness in severe physical exertion, Painful conditions of the musculoskeletal system, Pain in the musculoskeletal system, Pain in the muscles, Pain at rest, Muscle aches, Muscle pain, Musculoskeletal pain, Myalgia, Muscle pain, Muscle pain at rest, Muscle pain, Muscular pain of non-rheumatic origin, Muscle pain of rheumatic origin, Acute muscle pain, Rheumatic pain, Rheumatic pains, Myofascial syndrome, Fibromyalgia

R50 Fever of unknown origin

Malignant hyperthermia, Hyperthermia malignant

R52.1 Constant unrestrained pain

Pain syndrome in oncology practice, Pain syndrome pronounced, Pain syndrome in malignant neoplasms, Pain syndrome in cancer, Pain syndrome with tumors, Pain syndrome in cancer patients, Pain in malignant neoplasms, Pain in malignant tumors, Pain in tumors, Pain in cancer patients, Pain in bone metastases, Pain in cancer, Malignant pain syndrome, Intensive chronic pain, Intensive pain syndrome, Intensive non-curable pain syndrome, Intensive chronic pain syndrome, Unrestrained pain, Unrestrained pain, Tumor pain, Post-traumatic pain syndrome, Severe pain, Chronic pain, Chronic Pain Syndrome

R52.2 Other constant pain

Pain syndrome, rheumatic origin, Pain at vertebral lesions, Pain in the chamber, Pain for burns, Pain syndrome weak or moderate, Perioperative pain,Moderate to severe pain, Moderately or weakly expressed pain syndrome, Moderate to severe pain, Ear pain of otitis, Neuropathic pain, neuropathic pain

Composition and form of release

1 tablet contains 400 mg of acetylsalicylic acid and 32 mg of caffeine; in the bottle 50 pcs.

pharmachologic effect

Pharmacological action - antipyretic, analgesic.

Acetylsalicylic acid blocks cyclooxygenase and disrupts the synthesis of PG, caffeine increases the permeability of the BBB (blood-brain barrier) and increases the concentration of acetylsalicylic acid in the brain.

Indications for Ascaff

Moderate and strong pain syndrome of various etiology (including myalgia, arthralgia, toothache). Fever for colds and acute respiratory viral infection (acute respiratory viral infection).

Contraindications

Hypersensitivity, peptic ulcer of the stomach and duodenum in the acute stage, gastrointestinal bleeding, hemorrhagic diathesis, gout, bronchial asthma, renal and hepatic insufficiency, pregnancy, early childhood.

Side effects

Nausea, vomiting, epigastric pain, sleep disorders, skin itching, urticaria, bronchospasm.

Interaction

Strengthens the side effects of glucocorticoids, methotrexate, the main - derivatives of sulfonylurea, anticoagulants, weakens - spironolactone, furosemide, probenecid.

Dosing and Administration

Inside, washing down with water, - 1-2 tables. 4 times a day. The maximum daily dose is 10 tablets.

Precautionary measures

With caution combine with glucocorticoids, methotrexate, anticoagulants. It should avoid simultaneous use with barbiturates, anticonvulsants, salicylates, rifampicin, alcohol.

storage Conditions

In a dry, dark place at a temperature of 10-30 ° C.

Keep out of the reach of children.

Shelf life of Asquaff

2 years.

Do not use after the expiry date printed on the package.